Response To: 'COVID-19 in Patients with Rheumatological Diseases Treated with Anti-TNF' by Brito and 'Clinical Characteristics and Outcomes of Patients with COVID-19 and Rheumatic Disease in China 'hot Spot' Versus in US 'hot Spot': Similarities...
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Graef E, Liew J, Putman M, Simard J, Sirotich E, Berenbaum F
. : hydroxychloroquine, COVID-19 and the role of the rheumatologist. Ann Rheum Dis. 2020; 79(6):734-736.
PMC: 7359879.
DOI: 10.1136/annrheumdis-2020-217480.
View
2.
Mikuls T, Johnson S, Fraenkel L, Arasaratnam R, Baden L, Bermas B
. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020; 72(8):1241-1251.
DOI: 10.1002/art.41301.
View
3.
DSilva K, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese E
. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020; 79(9):1156-1162.
PMC: 7456555.
DOI: 10.1136/annrheumdis-2020-217888.
View
4.
Rosenberg E, Dufort E, Udo T, Wilberschied L, Kumar J, Tesoriero J
. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020; 323(24):2493-2502.
PMC: 7215635.
DOI: 10.1001/jama.2020.8630.
View
5.
Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y
. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020; 79(8):1007-1013.
PMC: 7295865.
DOI: 10.1136/annrheumdis-2020-217627.
View